In8Bio Inc (INAB)

$2.39 +0.10 (4.37%)
Market Cap 10.85M
Revenue (ttm) 0.00
Net Income (ttm) -30.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 44,900
Avg Vol 77,354
Day's Range N/A - N/A
Shares Out 4.54M
Stochastic %K 78%
Beta 0.03
Analysts Sell
Price Target $2.50

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 600 6438
Website: in8bio.com
Address:
350 5th Avenue, Suite 5330, New York, United States
Schizoo
Schizoo Oct. 4 at 7:30 PM
$INAB
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:34 PM
$DUO $BOLT $AEMD $INAB Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:43 AM
$AEMD $INAB $OGEN $AGMH :
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:38 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $AEMD $INAB $OGEN $AGMH 🚀
0 · Reply
Schizoo
Schizoo Oct. 2 at 5:01 PM
$INAB
0 · Reply
BioPharm_Swinger
BioPharm_Swinger Oct. 2 at 4:02 PM
$INAB https://stocktwits.com/PSM_EmpowerTrading/message/630527427
0 · Reply
BioPharm_Swinger
BioPharm_Swinger Oct. 2 at 3:55 PM
$INAB Data might be coming out anytime now! Huge upside imo
1 · Reply
Schizoo
Schizoo Oct. 2 at 3:41 PM
$INAB 🤌🚀
0 · Reply
BioPharm_Swinger
BioPharm_Swinger Oct. 2 at 3:18 PM
$INAB Looking good for a jump to $3+!
0 · Reply
AndreaRR
AndreaRR Oct. 1 at 2:25 PM
$INAB $TBH $DOGE.X
0 · Reply
Latest News on INAB
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 4:00 PM EDT - 2 months ago

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Jun 9, 2025, 7:00 AM EDT - 4 months ago

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

Jun 2, 2025, 7:30 AM EDT - 4 months ago

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

May 14, 2025, 8:00 AM EDT - 5 months ago

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

May 12, 2025, 8:00 AM EDT - 5 months ago

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 4:00 PM EDT - 5 months ago

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Apr 29, 2025, 8:00 AM EDT - 5 months ago

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

Apr 28, 2025, 8:00 AM EDT - 5 months ago

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

Mar 31, 2025, 8:00 AM EDT - 6 months ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Mar 18, 2025, 8:05 AM EDT - 7 months ago

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 13, 2025, 4:05 PM EDT - 7 months ago

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Mar 3, 2025, 9:28 AM EST - 7 months ago

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 7 months ago

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 24, 2025, 8:00 AM EST - 7 months ago

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Feb 14, 2025, 9:00 AM EST - 8 months ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Feb 11, 2025, 8:00 AM EST - 8 months ago

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Dec 10, 2024, 7:00 AM EST - 10 months ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 12, 2024, 4:26 PM EST - 11 months ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Sep 4, 2024, 4:01 PM EDT - 1 year ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 6:05 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Aug 12, 2024, 8:05 AM EDT - 1 year ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Jun 13, 2024, 4:01 PM EDT - 1 year ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

Jun 3, 2024, 6:05 AM EDT - 1 year ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 1 year ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

May 14, 2024, 10:00 AM EDT - 1 year ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

May 13, 2024, 8:00 AM EDT - 1 year ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 9, 2024, 4:00 PM EDT - 1 year ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

Apr 30, 2024, 6:05 AM EDT - 1 year ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 16, 2024, 4:05 PM EDT - 1 year ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Apr 9, 2024, 4:30 PM EDT - 1 year ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Mar 14, 2024, 4:00 PM EDT - 1 year ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 1 year ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio to Present at Upcoming Investor Conferences

Feb 26, 2024, 8:00 AM EST - 1 year ago

IN8bio to Present at Upcoming Investor Conferences

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Feb 14, 2024, 8:00 AM EST - 1 year ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Jan 4, 2024, 8:00 AM EST - 1 year ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Dec 11, 2023, 4:05 PM EST - 1 year ago

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Dec 11, 2023, 9:00 AM EST - 1 year ago

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Dec 7, 2023, 8:00 AM EST - 1 year ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

Dec 5, 2023, 8:00 AM EST - 1 year ago

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

Nov 20, 2023, 7:00 AM EST - 2 years ago

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Nov 10, 2023, 7:00 AM EST - 2 years ago

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 4:00 PM EST - 2 years ago

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Nov 6, 2023, 8:00 AM EST - 2 years ago

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Nov 3, 2023, 12:00 PM EDT - 2 years ago

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

Nov 2, 2023, 9:17 AM EDT - 2 years ago

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

Nov 1, 2023, 8:00 AM EDT - 2 years ago

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

Oct 12, 2023, 8:00 AM EDT - 2 years ago

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

Schizoo
Schizoo Oct. 4 at 7:30 PM
$INAB
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:34 PM
$DUO $BOLT $AEMD $INAB Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:43 AM
$AEMD $INAB $OGEN $AGMH :
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:38 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $AEMD $INAB $OGEN $AGMH 🚀
0 · Reply
Schizoo
Schizoo Oct. 2 at 5:01 PM
$INAB
0 · Reply
BioPharm_Swinger
BioPharm_Swinger Oct. 2 at 4:02 PM
$INAB https://stocktwits.com/PSM_EmpowerTrading/message/630527427
0 · Reply
BioPharm_Swinger
BioPharm_Swinger Oct. 2 at 3:55 PM
$INAB Data might be coming out anytime now! Huge upside imo
1 · Reply
Schizoo
Schizoo Oct. 2 at 3:41 PM
$INAB 🤌🚀
0 · Reply
BioPharm_Swinger
BioPharm_Swinger Oct. 2 at 3:18 PM
$INAB Looking good for a jump to $3+!
0 · Reply
AndreaRR
AndreaRR Oct. 1 at 2:25 PM
$INAB $TBH $DOGE.X
0 · Reply
C_FC
C_FC Sep. 30 at 11:33 PM
$INAB $CAPR $PGEN $IBB $BTK
0 · Reply
C_FC
C_FC Sep. 30 at 7:37 PM
$INAB $CAPR $PGEN $IBB $BTK
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Sep. 30 at 7:17 PM
⏳️ Potential swing ideas 💡 $INAB recent 1/30 reverse split, small float, recently announced patient 009 in phase 1 trial of INB-200 for newly-diagnosed (glioblastoma multiforme) GBM has reached a significant clinical milestone—achieving a 4-year remission, which far surpasses the progression-free outcomes observed in other clinical trials involving IDH-mutant glioma patients, Soumit Roy buy rating, analyst strong boy rating, HC Wainwright price target $6, company focuses on advancing gamma-delta (γδ) T cell-based therapies targeting cancer and autoimmune diseases, upcoming catalysts: 1) late summer and fall, continued interim data on phase 1/2 trials $TBH Recently announced $4M investment in CleanCore's $DOGE.X treasury model, recently launched secure digital assets platform for NIL initiative, recently featured on RedChip small stocks, big money show on Bloomberg TV, Zacks Small-cap research price target $4.40, company operates a Gen-Z focused esports and gaming platform
2 · Reply
Schizoo
Schizoo Sep. 30 at 2:56 PM
$INAB
0 · Reply
BioPharm_Swinger
BioPharm_Swinger Sep. 29 at 2:57 PM
$INAB could move fast! Long due for a post RS run! Clinical Data coming anytime. $14M cash. Good place to start a position imo. My target is $4!!
0 · Reply
Schizoo
Schizoo Sep. 26 at 6:24 PM
$INAB $IXHL $ONCO $PLRZ BALLS N PATIENCE
0 · Reply
kshonstocks
kshonstocks Sep. 26 at 2:43 PM
$INAB 50 dma area, keep an eye
0 · Reply
Schizoo
Schizoo Sep. 26 at 1:50 PM
$INAB 🤌
0 · Reply